Back to search

Article

Pre-MEASURE:<i>FLT3</i>-ITD and mutated<i>NPM1</i>measurable residual disease before allogeneic transplant in adults with AML in first remission

2022-10-22

Abstract excerpt

<h4>Background</h4> Prevention of relapse for adults with Acute Myeloid Leukemia (AML) in first remission (CR1) is the most common indication for allogeneic hematopoietic cell transplantation (alloHCT). Measurable residual disease (MRD) detection has been associated with higher relapse rates, but testing is not standardized. Establishment of validated AML MRD criteria would allow harmonization across centers facil...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e2df482e-9f5b-596d-8e63-00f9114e1abf
DOI
10.1101/2022.10.21.22281322
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pre-MEASURE:<i>FLT3</i>-ITD and mutated<i>NPM1</i>measurable residual disease before allogeneic transplant in adults with AML in first remissionDOI 10.1101/2022.10.21.22281322
Measurable Residual<i>IDH1</i>before Allogeneic Transplant for Acute Myeloid LeukemiaSemantic proximity
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.Semantic proximity
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.Semantic proximity
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid LeukemiaSemantic proximity
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity
Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity
Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.Semantic proximity
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Semantic proximity
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity
Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.Semantic proximity
Select a neighboring publication to make it the new centre.